Principales factores asociados al coste de la diabetes mellitus tipo 2: revisión de la literatura

Wild, 2004, Global prevalence of diabetes estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 Soriguer, 2012, Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The [email protected] Study, Diabetologia, 55, 88, 10.1007/s00125-011-2336-9 Ministerio de Sanidad, Servicios Sociales e Igualdad. Encuesta nacional de Salud (ENSE 2011/12) [consultado 14 Ene 2013]. Disponible en: http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/encuesta2011.htm Valdés, 2007, Evolución de la prevalencia de la diabetes tipo 2 en población adulta española, Med Clin (Barc), 129, 352, 10.1157/13109554 Oglesby, 2006, The association between diabetes related medical costs and glycemic control: A retrospective analysis, Cost Eff Resour Alloc, 4, 1, 10.1186/1478-7547-4-1 Zoungas, 2010, Severe hypoglycemia and risks of vascular events and death, N Engl J Med, 363, 1410, 10.1056/NEJMoa1003795 Zhao, 2012, Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes, Diabetes Care, 35, 1126, 10.2337/dc11-2048 Breitscheidel, 2010, Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: A review paper, J Med Econ, 13, 8, 10.3111/13696990903479199 Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683 CCEMG – EPPI-Centre Cost Converter’ [consultado 11 Dic 2012]. Disponible en: http://eppi.ioe.ac.uk/costconversion/default.aspx Jönsson, 2002, Revealing the cost of type II diabetes in Europe, Diabetologia, 45, S5, 10.1007/s00125-002-0858-x Schmitt-Koopmann, 2004, Direct medical costs of type 2 diabetes and its complications in Switzerland, Eur J Public Health, 14, 3, 10.1093/eurpub/14.1.3 Athanasakis, 2010, Estimating the direct cost of type 2 diabetes in Greece: The effects of blood glucose regulation on patient cost, Diabet Med, 27, 679, 10.1111/j.1464-5491.2010.03004.x Weber, 2007, Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: A Swiss perspective (ROSSO study No.11), Swiss Med Wkly, 137, 545 Jones, 2012, Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: Data from the INSTIGATE study, Clinicoecon Outcomes Res, 4, 383, 10.2147/CEOR.S36148 Hex, 2012, Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs, Diabet Med, 29, 855, 10.1111/j.1464-5491.2012.03698.x Mata, 2002, The cost of type 2 diabetes in Spain: The CODE-2 study, Gac Sanit, 16, 511, 10.1016/S0213-9111(02)71973-0 Neeser, 2009, Cost impact of self-measurement of blood glucose on complications of type 2 diabetes: The Spanish perspective, Diabetes Technol Ther, 11, 509, 10.1089/dia.2008.0139 Costi, 2011, Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: The INSTIGATE Study, Endocrinol Nutr, 58, 274, 10.1016/j.endonu.2011.03.004 Williams, 2002, Assessing the impact of complications on the costs of type II diabetes, Diabetologia, 45, S13, 10.1007/s00125-002-0859-9 Fu, 2010, Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe: A matched study, Diabetes Obes Metab, 12, 631, 10.1111/j.1463-1326.2010.01200.x Pelletier, 2009, Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: Results from a US claims data analysis, Pharmaeconomics, 27, 479, 10.2165/00019053-200927060-00004 O’Brien, 2003, Cost of managing complications resulting from type 2 diabetes mellitus in Canada, BMC Health Serv Res, 3, 7, 10.1186/1472-6963-3-7 O’Brien, 2003, Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000, Clin Ther, 25, 1017, 10.1016/S0149-2918(03)80122-4 Clarke, 2010, Event rates, hospital utilization, and costs associated with major complications of diabetes: A multicountry comparative analysis, PLoS Med, 7, e1000236, 10.1371/journal.pmed.1000236 Hammer, 2009, Costs of managing severe hypoglycaemia in three European countries, J Med Econ, 12, 281, 10.3111/13696990903336597 Davis, 2005, Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes, Curr Med Res Opin, 21, 1477, 10.1185/030079905X61929 Williams, 2012, The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients, J Diabetes Complications, 26, 399, 10.1016/j.jdiacomp.2012.05.002 Bron, 2012, Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs, Postgrad Med, 124, 124, 10.3810/pgm.2012.01.2525 Curkendall, 2011, Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: Analysis of a health insurance database, J Clin Outcomes Manage, 18, 455 Quilliam, 2011, The incidence and cost of hypoglycemia in type 2 diabetes, Am J Manag Care, 17, 673 Balkrishnan, 2003, Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study, Clin Ther, 25, 2958, 10.1016/S0149-2918(03)80347-8 Lau, 2004, Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes, Diabetes Care, 27, 2149, 10.2337/diacare.27.9.2149 Dilla, 2012, Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: The ECOBIM study, Appl Health Econ Health Policy, 10, 417, 10.1007/BF03261876 Von Lengerke, 2010, Excess health care cost of obesity in adults with diabetes mellitus: A claims data analysis, Exp Clin Endocrinol Diabetes, 118, 496, 10.1055/s-0030-1253400 Yu, 2007, Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: Analysis using claims, laboratory, and medical record data, Curr Med Res Opin, 23, 2157, 10.1185/0300799007X219544 Tao, 2010, Estimating the cost of type 1 diabetes in the US.: A propensity score matching method, PlosOne, 5, e11501, 10.1371/journal.pone.0011501 Dall, 2009, Distinguishing the economic costs associated with type 1 and type 2 diabetes, Popul Health Manag, 12, 103, 10.1089/pop.2009.12203 Malanda, 2012, Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin, Cochrane Database Syst Rev, 18, 1CD005060 Donner, 2012, Update on insulin therapy for type 2 diabetes, J Clin Endocrinol Metab, 97, 1405, 10.1210/jc.2011-2202 Korytkowski, 2002, When oral agents fail: Practical barriers to starting insulin, Int J Obes Relat Metab Disord, 26, S18, 10.1038/sj.ijo.0802173 Kostev, 2013, Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: A retrospective database analysis in Germany, France, and UK, Prim Care Diabetes, 7, 167, 10.1016/j.pcd.2013.02.001 Ha, 2012, Severe hypoglycemia is a serious complication and becoming an economic burden in diabetes, Diabetes Metab J, 36, 280, 10.4093/dmj.2012.36.4.280 Alvarez-Guisasola, 2008, Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study, Diabetes Obes Metab, 10, 25, 10.1111/j.1463-1326.2008.00882.x Rozenfeld, 2008, Oral antidiabetic medication adherence and glycemic control in managed care, Am J Manag Care, 14, 71 Gelhorn, 2013, Preferences for medication attributes among patients with type 2 diabetes mellitus in the United Kingdom, Diabetes Obes Metab, 15, 802, 10.1111/dom.12091 Dias Barbosa, 2012, A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence, Patient Prefer Adherence, 6, 39, 10.2147/PPA.S24752 Smyth, 2006, Diabetes and obesity: The twin epidemics, Nat Med, 12, 75, 10.1038/nm0106-75 Phung, 2010, Effect of noninsulin antidiabetic drugs added to metfromin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes, JAMA, 303, 10.1001/jama.2010.405 Boletín Oficial del Estado, núm. 98, 24 de abril de 2012. Disponible en: http://www.boe.es/boe/dias/2012/04/24/pdfs/BOE-A-2012-5403.pdf